Ernexa Therapeutics Inc. Earnings Per Share Disclosure
| 14) | Basic and Diluted Net Loss per Common Share |
| Years ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Numerator: | ||||||||
| Net loss attributable to common stockholders | $ | (44,555 | ) | $ | (21,684 | ) | ||
| Denominator: | ||||||||
| Weighted average shares outstanding - basic and diluted | ||||||||
| Net loss per common share - basic and diluted | $ | ) | $ | ) | ||||
Since the Company was in a net loss position for all periods presented, the net loss per share attributable to common stockholders was the same on a basic and diluted basis, as the inclusion of all potential common equivalent shares outstanding would have been anti-dilutive.
| Years ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Stock options | 2,629 | 389 | ||||||
| Warrants | 484 | 18,922 | ||||||
| Preferred stock converted into common stock | 31 | 18 | ||||||
| Convertible Notes converted into common stock | 7,877 | |||||||
| RSUs | 1 | |||||||
| Total potential common shares excluded from computation | 3,144 | 27,207 | ||||||
Want the next Ernexa Therapeutics Inc. earnings per share disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Ernexa Therapeutics Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.